ClinConnect ClinConnect Logo
Search / Trial NCT05965622

(Cost)-Effectiveness of ABFT for Suicidal Youth.

Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Jul 19, 2023

Trial Information

Current as of November 14, 2025

Recruiting

Keywords

Suicidality In Young Adults Attachment Based Family Therapy (Cost) Effectiveness

ClinConnect Summary

This clinical trial is studying a type of therapy called Attachment-Based Family Therapy (ABFT) to see if it is more effective than current treatments for young adults who have serious thoughts about suicide. The trial is taking place in Belgium and the Netherlands, aiming to include 138 participants aged between 18 and 25 years old. To participate, individuals must have a high level of suicidal thoughts and need to have at least one parent or caregiver involved in their treatment. The goal is to find out if ABFT can reduce suicidal thoughts and attempts better than the existing treatment options and if it offers good value for money.

Participants in the trial can expect to receive either ABFT or the standard treatment available. The study will take place in various settings, including hospitals and mental health centers. By participating, individuals will contribute to important research that could improve care for young adults at high risk of suicide, helping to shape future treatment guidelines and support for their families.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Aged between 18 and 25.
  • A score above 31 on the SIQ-JR (the cut-off for suicidality).
  • Have at least one primary parent or caregiver that participates in the assessment and treatment. This could be a biological parent, stepparent, grandparent, other relative, or a foster parent.
  • Exclusion Criteria:
  • Other DSM-5 disorders: substance dependency: severe alcohol or cannabis use disorder, all other substances: modest or severe substance use disorder.
  • Severe conduct disorder.
  • Evidence of psychotic features or prior psychosis (assessed with the SCID-5-S).
  • Severe cognitive impairment (e.g., mental retardation, severe developmental disorders) as evidenced by educational records, parental report and/or clinical impression.
  • Other circumstances that might affect participation (e.g., severe medical disorder, relocation).

About Academisch Medisch Centrum Universiteit Van Amsterdam (Amc Uva)

The Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is a leading academic medical center in the Netherlands, dedicated to advancing healthcare through innovative research, education, and patient care. Affiliated with the University of Amsterdam, AMC-UvA integrates clinical practice with cutting-edge biomedical research, fostering a multidisciplinary approach to medical challenges. The institution actively engages in clinical trials to enhance treatment options and improve patient outcomes, while promoting collaboration among healthcare professionals, researchers, and academic institutions globally. With a commitment to excellence and a focus on translational medicine, AMC-UvA plays a pivotal role in shaping the future of healthcare.

Locations

Amsterdam, Noord Holland, Netherlands

Oss, Noord Holland, Netherlands

Tongeren, Limburg, Belgium

Gent, Oost Vlaanderen, Belgium

Kortenberg, Vlaams Brabant, Belgium

Leuven, Vlaams Brabant, Belgium

Leuven, Vlaams Brabant, Belgium

Merchtem, Vlaams Brabant, Belgium

Eindhoven, Noord Brabant, Netherlands

Oss, Noord Brabant, Netherlands

Amsterdam, Noord Holland, Netherlands

Amsterdam, Noord Holland, Netherlands

Santpoort Noord, Noord Holland, Netherlands

Amersfoort, Utrecht, Netherlands

Patients applied

0 patients applied

Trial Officials

Nadia van der Spek, PhD

Study Director

Academic Medical Center (AMC)

Claudi Bockting, professor

Principal Investigator

Academic Medical Center (AMC)

Guy Bosmans, Professor

Study Director

KU Leuven

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported